Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caplacizumab without plasma exchange in iTTP
NCT05468320Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2022
- Primary completion
- Dec 2024
- Modality
- Nanobodies (VHH)
- Countries
- 11
01
Overview
A Phase 3 trial of caplacizumab in thrombotic thrombocytopenic purpura (TTP), sponsored by Sanofi. Started Nov 2022; status: completed.
02
Drugs
caplacizumab
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on NCT05468320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05468320.